Medifarma Laboratories is a leading toll-manufacturing pharmaceutical company based in Indonesia, specializing in the production of high-volume oral solid dosage forms. Established in 1970, the company operates a 36,595 square meter facility in Depok, on the southern outskirts of Jakarta. Medifarma is committed to providing affordable, high-quality pharmaceutical products and services, adhering to stringent Good Manufacturing Practices (GMP) as certified by the Indonesian National Agency of Drug and Food Control (NADFC), the Pharmaceutical Inspection Co-operation Scheme (PIC/S), and the World Health Organization (WHO).
Key Strategic Focus
Medifarma's strategic focus centers on contract and toll manufacturing, offering end-to-end services tailored to client requirements. The company specializes in high-volume production of oral solid dosage forms and is actively involved in new product development, collaborating with clients from concept to launch. Medifarma exports its products to several countries, including the Philippines, Singapore, Malaysia, Hong Kong, Myanmar, Cambodia, and Vietnam, thereby strengthening its presence in the Southeast Asian pharmaceutical market.
Financials and Funding
Medifarma Laboratories is a privately held company and does not publicly disclose detailed financial information. However, its sustained operations and ongoing facility expansions indicate a stable financial position. Notably, on January 23, 2023, Medifarma held a groundbreaking ceremony to commence the first phase of its factory expansion, aimed at meeting increasing customer demands and accommodating new clients.
Technological Platform and Innovation
Medifarma's production facility and operations are certified by the Indonesian NADFC, adhering to current GMP standards and meeting the requirements set by PIC/S and WHO. This compliance underscores the company's commitment to maintaining high-quality manufacturing practices.
Leadership Team
Medifarma Laboratories operates as an affiliate of United Laboratories, Inc. (Unilab), the largest pharmaceutical company in the Philippines. This affiliation provides Medifarma with strategic guidance and leadership support from Unilab's experienced executive team.
Competitor Profile
Market Insights and Dynamics: The pharmaceutical manufacturing industry in Indonesia is competitive, with a focus on producing affordable, high-quality medications to meet the healthcare needs of the region. The market is characterized by a mix of local and multinational companies striving to expand their market share through innovation and strategic partnerships.
Competitor Analysis: Key competitors in the Indonesian pharmaceutical manufacturing sector include:
- PT. Medion Farma Jaya: Specializes in producing and marketing pharmaceutical products, vitamins, vaccines, and poultry equipment, with over 40 years of experience.
- PT. Rohto Laboratories Indonesia: A subsidiary of Rohto Pharmaceutical Company, Ltd., focusing on over-the-counter medicines and consumer healthcare products.
- PT. Bio Farma: A leader in vaccine production in Indonesia, committed to combating infectious diseases both domestically and globally.
These competitors emphasize quality manufacturing practices and have established significant market presence in Indonesia.
Strategic Collaborations and Partnerships
Medifarma Laboratories is an affiliate of United Laboratories, Inc. (Unilab), the largest pharmaceutical company in the Philippines. This affiliation provides Medifarma with strategic guidance and leadership support from Unilab's experienced executive team.
Operational Insights
Medifarma's strategic considerations include leveraging its affiliation with Unilab to enhance market position and competitive advantages. The company's commitment to GMP compliance and facility expansion positions it to meet increasing customer demands and adapt to market dynamics effectively.
Strategic Opportunities and Future Directions
Medifarma's strategic roadmap includes expanding its manufacturing capabilities through facility enhancements and strengthening its presence in Southeast Asian markets. The company's focus on high-volume oral solid dosage forms and commitment to quality positions it to capitalize on the growing demand for affordable pharmaceuticals in the region.
Contact Information
- Website: Medifarma Laboratories
- LinkedIn: PT. Medifarma Laboratories
Please note that specific contact details such as physical address, phone number, and email are not provided in this profile.
